|
1
|
Pabst C, Krosl J, Fares I, Boucher G, Ruel
R, Marinier A, Lemieux S, Hébert J and Sauvageau G: Identification
of small molecules that support human leukemia stem cell activity
ex vivo. Nat Methods. 11:436–442. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shlush LI, Zandi S, Mitchell A, Chen WC,
Brandwein JM, Gupta V, Kennedy JA, Schimmer AD, Schuh AC, Yee KW,
et al: Identification of pre-leukaemic haematopoietic stem cells in
acute leukaemia. Nature. 506:328–333. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang H, Mi JQ, Fang H, Wang Z, Wang C, Wu
L, Zhang B, Minden M, Yang WT, Wang HW, et al: Preferential
eradication of acute myelogenous leukemia stem cells by
fenretinide. Proc Natl Acad Sci USA. 110:5606–5611. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matsushita H, Nakajima H, Nakamura Y,
Tsukamoto H, Tanaka Y, Jin G, Yabe M, Asai S, Ono R, Nosaka T, et
al: C/EBPalpha and C/EBPvarepsilon induce the monocytic
differentiation of myelomonocytic cells with the MLL-chimeric
fusion gene. Oncogene. 27:6749–6760. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wiley JM and Yeager AM: Predictive value
of colony-forming unit assays for engraftment and leukemia-free
survival after transplantation of chemopurged syngeneic bone marrow
in rats. Exp Hematol. 19:179–84. 1991.PubMed/NCBI
|
|
6
|
David H: Rudolf Virchow and modern aspects
of tumor pathology. Pathol Res Pract. 183:356–364. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boyerinas B, Zafrir M, Yesilkanal AE,
Price TT, Hyjek EM and Sipkins DA: Adhesion to osteopontin in the
bone marrow niche regulates lymphoblastic leukemia cell dormancy.
Blood. 121:4821–4831. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wiseman DH, Greystoke BF and Somervaille
TC: The variety of leukemic stem cells in myeloid malignancy.
Oncogene. 33:3091–3098. 2014. View Article : Google Scholar
|
|
9
|
Breiteneder-Geleff S, Soleiman A, Kowalski
H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler
E, Alitalo K and Kerjaschki D: Angiosarcomas express mixed
endothelial phenotypes of blood and lymphatic capillaries:
Podoplanin as a specific marker for lymphatic endothelium. Am J
Pathol. 154:385–394. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schacht V, Ramirez MI, Hong YK, Hirakawa
S, Feng D, Harvey N, Williams M, Dvorak AM, Dvorak HF, Oliver G and
Detmar M: T1alpha/podoplanin deficiency disrupts normal lymphatic
vasculature formation and causes lymphedema. EMBO J. 22:3546–3556.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kawase A, Ishii G, Nagai K, Ito T, Nagano
T, Murata Y, Hishida T, Nishimura M, Yoshida J, Suzuki K and Ochiai
A: Podoplanin expression by cancer associated fibroblasts predicts
poor prognosis of lung adenocarcinoma. Int J Cancer. 123:1053–1059.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamanashi T, Nakanishi Y, Fujii G,
Akishima-Fukasawa Y, Moriya Y, Kanai Y, Watanabe M and Hirohashi S:
Podoplanin expression identified in stromal fibroblasts as a
favorable prognostic marker in patients with colorectal carcinoma.
Oncology. 77:53–62. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kadota K, Huang CL, Liu D, Nakashima N,
Yokomise H, Ueno M and Haba R: The clinical significance of the
tumor cell D2-40 immunoreactivity in non-small cell lung cancer.
Lung cancer. 70:88–93. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee JY, Park S, Kim DC, Yoon JH, Shin SH,
Min WS and Kim HJ: A VEGFR-3 antagonist increases IFN-γ expression
on low functioning NK cells in acute myeloid leukemia. J Clin
Immunol. 33:826–837. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Conrad C, Niess H, Huss R, Huber S, von
Luettichau I, Nelson PJ, Ott HC, Jauch KW and Bruns CJ: Multipotent
mesenchymal stem cells acquire a lymphendothelial phenotype and
enhance lymphatic regeneration in vivo. Circulation. 119:281–289.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raica M, Cimpean AM and Ribatti D: The
role of podoplanin in tumor progression and metastasis. Anticancer
Res. 28:2997–3006. 2008.PubMed/NCBI
|
|
17
|
Schacht V, Dadras SS, Johnson LA, Jackson
DG, Hong YK and Detmar M: Up-regulation of the lymphatic marker
podoplanin, a mucin-type transmembrane glycoprotein, in human
squamous cell carcinomas and germ cell tumors. Am J Pathol.
166:913–921. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wicki A and Christofori G: The potential
role of podoplanin in tumour invasion. Br J Cancer. 96:1–5. 2007.
View Article : Google Scholar
|
|
19
|
Vardiman JW, Thiele J, Arber DA, Brunning
RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM,
Hellström-Lindberg E, Tefferi A and Bloomfield CD: The 2008
revision of the World Health Organization (WHO) classification of
myeloid neoplasms and acute leukemia: Rationale and important
changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bae DS and Lee JK: Development of NK cell
expansion methods using feeder cells from human myelogenous
leukemia cell line. Blood Res. 49:154–161. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee JY, Park C, Cho YP, Lee E, Kim H, Kim
P, Yun SH and Yoon YS: Podoplanin-expressing cells derived from
bone marrow play a crucial role in postnatal lymphatic
neovascularization. Circulation. 122:1413–1425. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Koh CM: Preparation of cells for
microscopy using cytospin. Methods Enzymol. 533:235–240. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ariizumi T, Ogose A, Kawashima H, Hotta T,
Li G, Xu Y, Umezu H, Sugai M and Endo N: Expression of podoplanin
in human bone and bone tumors: New marker of osteogenic and
chondrogenic bone tumors. Pathol Int. 60:193–202. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gishizky ML and Witte ON: Initiation of
deregulated growth of multipotent progenitor cells by bcr-abl in
vitro. Science. 256:836–839. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng H, Hao S, Liu Y, Pang Y, Ma S, Dong
F, Xu J, Zheng G, Li S, Yuan W and Cheng T: Leukemic marrow
infiltration reveals a novel role for Egr3 as a potent inhibitor of
normal hematopoietic stem cell proliferation. Blood. 126:1302–1313.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Drexler HG: Expression of FLT3 receptor
and response to FLT3 ligand by leukemic cells. Leukemia.
10:588–599. 1996.PubMed/NCBI
|
|
28
|
Rosnet O, Bühring HJ, Marchetto S, Rappold
I, Lavagna C, Sainty D, Arnoulet C, Chabannon C, Kanz L, Hannum C
and Birnbaum D: Human FLT3/FLK2 receptor tyrosine kinase is
expressed at the surface of normal and malignant hematopoietic
cells. Leukemia. 10:238–248. 1996.PubMed/NCBI
|
|
29
|
Meshinchi S and Appelbaum FR: Structural
and functional alterations of FLT3 in acute myeloid leukemia. Clin
Cancer Res. 15:4263–4269. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Patel JP, Gonen M, Figueroa ME, Fernandez
H, Sun Z, Racevskis J, van Vlierberghe P, Dolgalev I, Thomas S,
Aminova O, et al: Prognostic relevance of integrated genetic
profiling in acute myeloid leukemia. N Engl J Med. 366:1079–1089.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Miyoshi H, Shimizu K, Kozu T, Maseki N,
Kaneko Y and Ohki M: t(8;21) breakpoints on chromosome 21 in acute
myeloid leukemia are clustered within a limited region of a single
gene, AML1. Proc Natl Acad Sci USA. 88:10431–10434. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim HJ, Choi EJ, Sohn HJ, Park SH, Min WS
and Kim TG: Combinatorial molecular marker assays of WT1, survivin
and TERT at initial diagnosis of adult acute myeloid leukemia. Eur
J Haematol. 91:411–422. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Suzuki S, Ishii G, Matsuwaki R, Neri S,
Hashimoto H, Yamauchi C, Aokage K, Hishida T, Yoshida J, Kohno M,
et al: Ezrin-expressing lung adenocarcinoma cells and
podoplanin-positive fibroblasts form a malignant microenvironment.
J Cancer Res Clin Oncol. 141:475–484. 2015. View Article : Google Scholar
|
|
34
|
Chuang WY, Yeh CJ, Chao YK, Liu YH, Chang
YS, Tseng CK, Chang HK, Wan YL and Hsueh C: Concordant podoplanin
expression in cancer-associated fibroblasts and tumor cells is an
adverse prognostic factor in esophageal squamous cell carcinoma.
Int J Clin Exp Pathol. 7:4847–4856. 2014.PubMed/NCBI
|
|
35
|
Dang Q, Liu J, Li J and Sun Y: Podoplanin:
A novel regulator of tumor invasion and metastasis. Med Oncol.
31(24)2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee JY and Kim HJ: (Lymph) angiogenic
influences on hematopoietic cells in acute myeloid leukemia. Exp
Mol Med. 46:e1222014. View Article : Google Scholar
|
|
37
|
Lee JY, Park S, Min WS and Kim HJ:
Restoration of natural killer cell cytotoxicity by VEGFR-3
inhibition in myelogenous leukemia. Cancer lett. 354:281–289. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Junttila MR and de Sauvage FJ: Influence
of tumour micro-environment heterogeneity on therapeutic response.
Nature. 501:346–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chang YW, Hsieh PW, Chang YT, Lu MH, Huang
TF, Chong KY, Liao HR, Cheng JC and Tseng CP: Identification of a
novel platelet antagonist that binds to CLEC-2 and suppresses
podoplanin-induced platelet aggregation and cancer metastasis.
Oncotarget. 6:42733–42748. 2015.PubMed/NCBI
|
|
40
|
Grau SJ, Trillsch F, Tonn JC, Goldbrunner
RH, Noessner E, Nelson PJ and von Luettichau I: Podoplanin
increases migration and angiogenesis in malignant glioma. Int J
Clin Exp Pathol. 8:8663–8670. 2015.PubMed/NCBI
|
|
41
|
Tanaka M, Kijima H, Shimada H, Makuuchi H,
Ozawa S and Inokuchi S: Expression of podoplanin and vimentin is
correlated with prognosis in esophageal squamous cell carcinoma.
Mol Med Rep. 12:4029–4036. 2015.PubMed/NCBI
|
|
42
|
Kim EK, Jeon I, Seo H, Park YJ, Song B,
Lee KA, Jang Y, Chung Y and Kang CY: Tumor-derived osteopontin
suppresses antitumor immunity by promoting extramedullary
myelopoiesis. Cancer Res. 74:6705–6716. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Blau O, Baldus CD, Hofmann WK, Thiel G,
Nolte F, Burmeister T, Türkmen S, Benlasfer O, Schümann E, Sindram
A, et al: Mesenchymal stromal cells of myelodysplastic syndrome and
acute myeloid leukemia patients have distinct genetic abnormalities
compared with leukemic blasts. Blood. 118:5583–5592. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Geyh S, Oz S, Cadeddu RP, Fröbel J,
Brückner B, Kündgen A, Fenk R, Bruns I, Zilkens C, Hermsen D, et
al: Insufficient stromal support in MDS results from molecular and
functional deficits of mesenchymal stromal cells. Leukemia.
27:1841–1851. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Konopleva M, Konoplev S, Hu W, Zaritskey
AY, Afanasiev BV and Andreeff M: Stromal cells prevent apoptosis of
AML cells by up-regulation of anti-apoptotic proteins. Leukemia.
16:1713–1724. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Flach J, Bakker ST, Mohrin M, Conroy PC,
Pietras EM, Reynaud D, Alvarez S, Diolaiti ME, Ugarte F, Forsberg
EC, et al: Replication stress is a potent driver of functional
decline in ageing haematopoietic stem cells. Nature. 512:198–202.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Schepers K, Pietras EM, Reynaud D, Flach
J, Binnewies M, Garg T, Wagers AJ, Hsiao EC and Passegué E:
Myeloproliferative neoplasia remodels the endosteal bone marrow
niche into a self-reinforcing leukemic niche. Cell Stem Cell.
13:285–299. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ishikawa F, Yoshida S, Saito Y, Hijikata
A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N,
et al: Chemotherapy-resistant human AML stem cells home to and
engraft within the bone-marrow endosteal region. Nat Biotechnol.
25:1315–1321. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Saito Y, Uchida N, Tanaka S, Suzuki N,
Tomizawa-Murasawa M, Sone A, Najima Y, Takagi S, Aoki Y, Wake A, et
al: Induction of cell cycle entry eliminates human leukemia stem
cells in a mouse model of AML. Nat Biotechnol. 28:275–280.
2010.PubMed/NCBI
|
|
50
|
Bendall LJ, Kortlepel K and Gottlieb DJ:
Human acute myeloid leukemia cells bind to bone marrow stroma via a
combination of beta-1 and beta-2 integrin mechanisms. Blood.
82:3125–3132. 1993.PubMed/NCBI
|
